Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2010
10/19/2010US7816335 Therapeutic compounds and methods
10/19/2010US7816075 treating a human afflicted with condition characterized by elevated serum triglyceride or very low density lipoprotein (VLDL), comprising the step of administering an inhibitor of human delta-9 stearoyl-CoA desaturase (SCD1) activity; coronary artery disease, Type II diabetes, obesity
10/19/2010CA2469346C Substituted 2-pyrrolidin-2-yl-1h-indole derivatives for treatment of migraine
10/19/2010CA2463284C Pyrimidine compounds and pharmaceutical compositions containing the compounds
10/19/2010CA2451422C Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
10/19/2010CA2448089C Thiolalkyl benzoic acid derivatives
10/19/2010CA2439791C Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/19/2010CA2437409C Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators
10/19/2010CA2437196C A composition for the treatment of heart failure comprising levosimendan and a calcium ion source and/or an intreacellular calcium increasing agent
10/19/2010CA2409743C Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
10/19/2010CA2374631C Benzene derivatives, process for their preparation and pharmaceutical compositions containing them
10/19/2010CA2362715C Quinazoline derivatives as angiogenesis inhibitors
10/19/2010CA2325803C Novel omega conotoxin peptides
10/19/2010CA2322860C Products containing polyphenol(s) and l-arginine to stimulate nitric oxide production
10/19/2010CA2321455C Indole-3-propionic acids, salts and esters thereof used as medicaments
10/19/2010CA2296704C Cardiac muscle regeneration using mesenchymal stem cells
10/19/2010CA2266757C Process for preparing pharmacologically acceptable salts of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanyl-amino acids
10/19/2010CA2186118C Compacted nucleic acids and their delivery to cells
10/15/2010CA2662650A1 Treatment and prevention of ischemic injury using activated protein c
10/14/2010WO2010118419A2 Novel anti-aging agents and methods to identify them
10/14/2010WO2010118330A2 Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease
10/14/2010WO2010117860A2 Microrna signature to predict prognosis in heart failure
10/14/2010WO2010117756A2 Substituted benzimidazole pharmaceutical formulations
10/14/2010WO2010117233A2 Stable pharmaceutical composition containing fluvastatin and method for manufacturing the same
10/14/2010WO2010117077A1 Therapeutic agent for chorioretinal diseases comprising sirolimus derivative as active ingredient
10/14/2010WO2010117055A1 Polypeptide having selective inhibitory activity on protein kinase cα or η
10/14/2010WO2010117040A1 Five-membered heterocyclic compound
10/14/2010WO2010116866A1 Agent for ameliorating or preventing metabolic syndrome
10/14/2010WO2010116673A1 Mitochondrial function-improving agent
10/14/2010WO2010116665A1 New revascularization cells derived from mononuclear cells, and method of inducing differentiation thereof
10/14/2010WO2010116380A2 A one pot process for preparing 2-butyl-3-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro [4, 4] non-1-en-4-one (irbesartan)
10/14/2010WO2010116282A1 4, 5-dihydro-lh-pyrazole compounds and their pharmaceutical uses
10/14/2010WO2010116090A1 Therapeutic applications in the cardiovascular field of quinazolinedione derivatives
10/14/2010WO2010115874A1 Methods for the treatment and the diagnosis ofpulmonary arterial hypertension
10/14/2010WO2010115548A1 Sulfonic amide and sulfoximine-substituted diaryl-dihydropyrimidinones and usage thereof
10/14/2010WO2010115491A2 Piperidine and piperazine derivatives as autotaxin inhibitors
10/14/2010WO2010089772A3 Chronotherapeutic pharmaceutical composition
10/14/2010WO2010077693A3 Method for identifying agents for inhibiting cell motility and invasiveness
10/14/2010WO2010060928A3 Compositions for the treatment of ischemic tissue damage
10/14/2010US20100261799 Stable and compatible polymer blends
10/14/2010US20100261790 Body-weight maintenance and body composition
10/14/2010US20100261789 Butenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and use for the treatment of dyslipidaemia, atherosclerosis and diabetes
10/14/2010US20100261788 Inhibition of Bid-Induced Cell-Death Using Small Organic Molecules
10/14/2010US20100261772 Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators
10/14/2010US20100261771 Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof
10/14/2010US20100261765 Mineralocorticoid receptor modulators
10/14/2010US20100261764 Substituted 3 -hydroxypyridines and pharmaceutical compositions thereof
10/14/2010US20100261758 Heterocyclic amides for use as pharmaceuticals
10/14/2010US20100261756 method for inhibiting platelet aggregation
10/14/2010US20100261755 Isoxazol-3(2h)-one analogs as therapeutic agents
10/14/2010US20100261743 Novel seh inhibitors and their use
10/14/2010US20100261742 Novel polymorphic forms
10/14/2010US20100261736 Substituted bicyclic heteroaryl compounds for the treatment of cardiovascular disease
10/14/2010US20100261718 N3 alkylated benzimidazole derivatives as mek inhibitors
10/14/2010US20100261717 N3 alkylated benzimidazole derivatives as mek inhibitors
10/14/2010US20100261715 Carbamate compounds which inhibit leukocyte adhesion mediated by vla-4
10/14/2010US20100261709 Pyridazinone derivatives as parp inhibitors
10/14/2010US20100261708 Diazepane Compounds Which Modulate The CB2 Receptor
10/14/2010US20100261706 Substituted tetracyclic 1h-indeno [1,2-b]pyridine-2(5h)-one analogs thereof and uses thereof
10/14/2010US20100261698 Organic compounds
10/14/2010US20100261687 Substituted piperidines as ccr3 antagonists
10/14/2010US20100261684 Pharmaceutical combination of medication to be used by patients presenting with an acute coronary syndrome so as to stop the process and prevent a myocardial infarction
10/14/2010US20100261678 Phosphonic acid derivates ad their use as p2y12 receptor antagonists
10/14/2010US20100261674 Therapeutic applications of fatty acid amide hydrolase inhibitors
10/14/2010US20100261666 Compositions and methods for the treatment of myocardial dysfunction associated with sirs or sepsis
10/14/2010US20100261662 Utilization of mural thrombus for local drug delivery into vascular tissue
10/14/2010US20100261654 Compositions and methods for increasing vascularization
10/14/2010US20100261647 Fusion proteins for delivery of erythropoietin to the cns
10/14/2010US20100261641 Spiro-piperidine compounds and medicinal use thereof
10/14/2010US20100261637 Peptides derivatized with a-b-c-d- and their therapeutical use
10/14/2010US20100261271 Regulation of endogenous gene expression in cells using zinc finger proteins
10/14/2010US20100260851 Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
10/14/2010US20100260841 Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
10/14/2010US20100260835 Pharmaceutical composition
10/14/2010US20100260825 Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches
10/14/2010US20100260785 SARP-1 Fusion Proteins and Uses Thereof
10/14/2010US20100260773 Antibody molecules having binding specificity for human il-13
10/14/2010US20100260750 Novel serotonin reuptake inhibitors as drugs having peripheral-system-restricted activity
10/14/2010US20100260749 Modulators of EphA2 and Ephrin-A1 for the treatment of fibrosis-related disease
10/14/2010US20100260742 Medicament and a method for regulation of the vascular tone
10/14/2010US20100260733 Novel anti aging agents and methods to identify them
10/14/2010US20100260727 Method to amplify cardiac stem cells in vitro and in vivo
10/14/2010US20100260714 Compositions comprising n3 alkylated benzimidazole derivatives as mek inhibitors and methods of use thereof
10/14/2010US20100260706 Compositions and methods for improving production of recombinant polypeptides
10/14/2010US20100260705 Products for altering il-33 activity and methods thereof
10/14/2010US20100260674 Quinazoline derivatives and methods of treatment
10/14/2010US20100260669 Treatment of Seasonal Conditions Through Modulation of the Autonomic Nervous System
10/14/2010US20100260668 Dual Variable Domain Immunoglobulins and Uses Thereof
10/14/2010DE102009016719A1 Composition, useful as pharmaceutical preparation for e.g. prophylaxis of lipid metabolic disorders in humans and animals and treating atherosclerosis, comprises 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor and solid material
10/14/2010CA2795907A1 Methods and compositions for inducing physiological hypertrophy
10/14/2010CA2758234A1 Therapeutic applications in the cardiovascular field of quinazolinedione derivatives
10/14/2010CA2758233A1 Quinazolinedione derivatives, preparation thereof and various therapeutic uses thereof
10/14/2010CA2757654A1 Sulfonic amide and sulfoximine-substituted diaryl-dihydropyrimidinones and usage thereof
10/14/2010CA2757368A1 Piperidine and piperazine derivatives as autotaxin inhibitors
10/14/2010CA2756542A1 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
10/14/2010CA2756272A1 Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease
10/14/2010CA2756250A1 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
10/13/2010EP2239325A1 Virus growing in hypoxic cell or virus vector expressing gene therein
10/13/2010EP2239270A2 Low molecular weight peptide derivatives as inhibitors of the Laminin/Nidogen interaction
10/13/2010EP2239268A1 Dipeptide derivatives
1 ... 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 ... 1595